Elixirgen Therapeutics, Inc.

This early-phase study tests a new treatment called EXG34217 in 12 people aged 12 and older who have bone marrow failure due to telomere biology disorders. The main goal is to see if the treatment is safe and tolerable. Researchers will also check if it improves blood cell counts…